{
  "id": 13132622,
  "title": "Targeting ribosome biogenesis sensitizes PARPi-resistant triple-negative breast cancer",
  "url": "https://urgent.news/2026/10/09/targeting-ribosome-biogenesis-sensitizes-parpi-resistant-triple",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-09T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.10.08.757577v1?rss=1"
  },
  "original_language": "en",
  "account": null,
  "summary": "Poly (ADP-ribose) polymerase inhibitors (PARPi) are the only targeted treatment available for early triple-negative breast cancer (TNBC), an aggressive subtype with limited treatment options. While PARPi are effective in patients with BRCA mutations, resistance to these inhibitors can arise. We previously developed BRCA-mutant cell lines, HCC1395, with acquired resistance to talazoparib and…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}